JANX-008 is under clinical development by Janux Therapeutics and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC). According to GlobalData, Phase I drugs for Head And Neck Squamous Cell Carcinoma (HNSC) have a 79% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how JANX-008’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
JANX-008 overview
JANX-008 is under development for the treatment of solid tumors including metastaic colorectal cancer, head and neck cancer squamous cell carcinoma, non-small cell lung cancer, metastatic renal cell carcinoma, small-cell lung cancer, pancreatic ductal adenocarcinoma and triple-negative breast cancer. It comprises of a bi-specific fusion protein that acts by targeting cells expressing EGFR and CD3. It is administered through intravenous route and is being developed based on tumor activated T Cell engager (TRACTr) technology.
Janux Therapeutics overview
Janux Therapeutics (Janux) is a clinical-stage biopharmaceutical company that develops novel immunotherapies to treat cancer. The company’s novel proprietary platforms T cell engager (TRACTr), and tumor activated immunomodulator (TRACIr) facilitate the manufacturing of monoclonal antibodies that delivers drug candidates. Janux products pipeline includes JANX007 and JANX008 that target prostate-specific membrane antigen (PSMA) and epidermal growth factor receptor (EGFR). The company product pipelines are used to treat colorectal cancer, head and neck cancer, non-small cell lung cancer, and other solid tumors. Janux is headquartered in San Diego, California, the U.S.
For a complete picture of JANX-008’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
